title: Secondary structure peptide mimetics: design, synthesis, and evaluation of beta-strand mimetic thrombin inhibitors.
abstract: Constrained dipeptide mimetic templates were designed to mimic the secondary structure of peptides in a beta-strand conformation. Two templates corresponding to the D-Phe-Pro portion of the thrombin inhibitor D-Phe-Pro-ArgCH2Cl were synthesized and converted into nine alpha-ketoamide and alpha-ketoheterocycle inhibitors of thrombin. Additionally, a template corresponding to L-Phe-Pro was synthesized and converted to a thrombin inhibitor. The in vitro inhibition of thrombin by these compounds was determined, and those corresponding to the D-Phe-Pro were found to be more potent inhibitors than the L-Phe-Pro mimetic. The alpha-ketoamides were found to be more potent than the alpha-ketoheterocycles but had much slower on rates. By comparison of a series of alpha-ketoamide analogues, it is apparent that the there is a preference for binding of bulky hydrophobic substituents in the P' portion of the thrombin active site. Three of the inhibitors (MOL098, MOL144, and MOL174) were screened against a series of coagulation and anticoagulation enzymes and found to be selective for inhibition of the coagulation enzymes. Two of the inhibitors were tested in in vitro models of intestinal absorption and found to have low absorption potential. The compounds were then tested in vivo in both rats and primates, and one of them (MOL144) was approximately 25% absorbed in both species. This study has delineated the synthesis of constrained dipeptide beta-strand mimetics and validated the potential for compounds of this type as potent thrombin inhibitors and possible drug leads.
authors.affiliation: Molecumetics Ltd., 2023 120th Avenue NE, Suite 400, Bellevue, Washington 98005-2199, USA.
authors.forename: P D
authors.initials: PD
authors.lastname: Boatman
authors.forename: C O
authors.initials: CO
authors.lastname: Ogbu
authors.forename: M
authors.initials: M
authors.lastname: Eguchi
authors.forename: H O
authors.initials: HO
authors.lastname: Kim
authors.forename: H
authors.initials: H
authors.lastname: Nakanishi
authors.forename: B
authors.initials: B
authors.lastname: Cao
authors.forename: J P
authors.initials: JP
authors.lastname: Shea
authors.forename: M
authors.initials: M
authors.lastname: Kahn
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001682:Biological Availability; D018938:Caco-2 Cells; D018360:Crystallography, X-Ray; D015195:Drug Design; D006801:Humans; D007275:Injections, Intravenous; D008958:Models, Molecular; D018716:Molecular Mimicry; D010215:Papio; D010455:Peptides / Q000737:chemistry*; D017433:Protein Structure, Secondary; D051381:Rats; D015842:Serine Proteinase Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D013917:Thrombin / Q000037:antagonists & inhibitors*; D013927:Thrombosis / Q000473:pathology
chemical_list: D010455:Peptides; D015842:Serine Proteinase Inhibitors; D013917:Thrombin